Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Balanced, Single Dose, Three-treatment, Three-period, Crossover Bioavailability Study of Azithromycin Oleogel in Healthy, Adult, Human Subjects Under Fasting Condition.

Next Previous
Trial Profile

A Randomized, Balanced, Single Dose, Three-treatment, Three-period, Crossover Bioavailability Study of Azithromycin Oleogel in Healthy, Adult, Human Subjects Under Fasting Condition.

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Oct 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Azithromycin (Primary) ; Azithromycin; Azithromycin
  • Indications Acute sinusitis; Bacterial infections; Community-acquired pneumonia; COVID 2019 infections; Otitis media; Pelvic inflammatory disorders; Sexually transmitted infections
  • Focus Adverse reactions; Pharmacokinetics

Most Recent Events

  • 23 Sep 2025 Planned End Date changed from 1 Dec 2023 to 1 Oct 2025.
  • 23 Sep 2025 Planned primary completion date changed from 1 Nov 2023 to 1 Oct 2025.
  • 23 Sep 2025 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top